About: Tumor necrosis factor as a pharmacological target

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tumor necrosis factor as a pharmacological target Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Tumor necrosis factor as a pharmacological target
Creator	Ghezzi, Pietro Cerami, Anthony
source	PMC
abstract	As indicated by its name, tumor necrosis factor (TNF), cloned in 1985, was originally described as a macrophage-derived endogenous mediator that can induce hemorrhagic necrosis of solid tumors and kill some tumor cell lines in vitro. Unfortunately, its promising use as an anticancer agent was biased by its toxicity, which was clear soon from the first clinical trials with TNF in cancer. Almost at the same time TNF was being developed as an anticancer drug, it became clear that TNF was identical to a mediator responsible for cachexia associated with sepsis, which was termed cachectin. This research led to the finding that TNF is, in fact, the main lethal mediator of sepsis and to the publication of a huge number of articles showing that TNF inhibits the toxic effects of bacterial endotoxins, which are now described as systemic inflammatory response. Although the clinical trials with anti-TNF in sepsis have not been successful thus far, undoubtedly as a result of the complexity of this clinical setting, these studies ultimately led to the identification of TNF as a key inflammatory mediator and to the development of anti-TNF molecules (soluble receptors and antibodies) for important diseases including rheumatoid arthritis and Crohn’s disease. On the other side, the mechanisms by which TNF and related molecules induce cell death have been studied in depth, and their knowledge might, in the future, suggest means of improve the therapeutic index of TNF in cancer.
has issue date	2005-01-01(xsd:dateTime)
bibo:doi	10.1385/mb:31:3:239
bibo:pmid	16230774
has license	no-cc
sha1sum (hex)	7c506ebb4a4c74b60b7b21616ad5c7f7b14b2e22
schema:url	https://doi.org/10.1385/mb:31:3:239
resource representing a document's title	Tumor necrosis factor as a pharmacological target
has PubMed Central identifier	PMC7101943
has PubMed identifier	16230774
schema:publication	Mol Biotechnol
resource representing a document's body	covid:7c506ebb4a4c74b60b7b21616ad5c7f7b14b2e22#body_text
is schema:about of	named entity 'Pharmacological' named entity 'Target' named entity 'Tumor Necrosis Factor' named entity 'protease' named entity 'cytokines' named entity 'recombinant' named entity 'TNF' named entity 'TACE' named entity 'animal models' named entity 'TNF' named entity 'LPS' named entity 'TNF' named entity 'TNF' named entity 'GM-CSF' named entity 'TNF' named entity 'anti-TNF' named entity 'LPS' named entity 'plasma half-life' named entity 'photoaffinity label' named entity 'glucocorticoid receptor' named entity 'lymphocyte' named entity 'endogenous' named entity 'IL-1' named entity 'MOF' named entity 'systemic inflammatory response syndrome' named entity 'adrenal' named entity 'hematopoietic' named entity 'IL-4' named entity 'septic shock' named entity 'Crohn's disease' named entity 'cytokine' named entity 'cytokines' named entity 'TNF' named entity 'pharmacological' named entity 'adipocytes' named entity 'TNF' named entity 'TNF' named entity 'TNF' named entity 'classes of drugs' named entity 'IL-4' named entity 'cytokine' named entity 'lipopolysaccharide' named entity 'ARDS' named entity 'TNF' named entity 'pentoxifylline' named entity 'TNF' named entity 'aspirin' named entity 'kinase' named entity 'systemic inflammatory response' named entity 'TNF' named entity 'vagus nerve' named entity 'toid' named entity 'human urine' named entity 'TNF-mediated' named entity 'arthritis' named entity 'enzyme' named entity 'long time' named entity 'cytokines' named entity 'MAF' named entity 'mifepristone' named entity 'tumor cells' named entity 'p38 MAPK' named entity 'TNF' named entity 'mifepristone' named entity 'inflammation' named entity 'septic shock' named entity 'arthritis' named entity 'TNF' named entity 'live bacteria' named entity 'interleukin' named entity 'TNF' named entity 'American College of Chest Physicians' named entity 'antibodies' named entity 'glucocorticoid receptor' named entity 'SIRS' named entity 'cAMP' named entity 'nicotinic' named entity 'TNF' named entity 'endogenous' named entity 'TNF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software